137 related articles for article (PubMed ID: 32907824)
1. Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score.
Chu G; Valerio L; van der Wall SJ; Barco S; Konstantinides S; Huisman MV; Klok FA
Heart; 2020 Sep; ():. PubMed ID: 32907824
[TBL] [Abstract][Full Text] [Related]
2. External validation of AF-BLEED for predicting major bleeding and for tailoring NOAC dose in AF patients: A post hoc analysis in the ENGAGE AF-TIMI 48.
Chu G; Valerio L; Barco S; Huisman MV; Konstantinides SV; Klok FA
Thromb Res; 2023 Sep; 229():225-231. PubMed ID: 37566971
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
5. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
[TBL] [Abstract][Full Text] [Related]
6. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).
Nagarakanti R; Wallentin L; Noack H; Brueckmann M; Reilly P; Clemens A; Connolly SJ; Yusuf S; Ezekowitz MD
Am J Cardiol; 2015 Oct; 116(8):1204-9. PubMed ID: 26282726
[TBL] [Abstract][Full Text] [Related]
10. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk.
An J; Cheetham TC; Luong T; Lang DT; Lee MS; Reynolds K
Clin Ther; 2023 Jul; 45(7):e151-e158. PubMed ID: 37380555
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
[TBL] [Abstract][Full Text] [Related]
14. Effects of dabigatran according to age in atrial fibrillation.
Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
[TBL] [Abstract][Full Text] [Related]
15. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Salazar CA; del Aguila D; Cordova EG
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
[TBL] [Abstract][Full Text] [Related]
16. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
[TBL] [Abstract][Full Text] [Related]
17. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
Fernandez MM; Wang J; Ye X; Kwong WJ; Sherif B; Hogue S; Sherrill B
SAGE Open Med; 2015; 3():2050312115613350. PubMed ID: 27092254
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
Ruff CT; Giugliano RP; Braunwald E; Hoffman EB; Deenadayalu N; Ezekowitz MD; Camm AJ; Weitz JI; Lewis BS; Parkhomenko A; Yamashita T; Antman EM
Lancet; 2014 Mar; 383(9921):955-62. PubMed ID: 24315724
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant.
Taoutel R; Ezekowitz MD; Chaudhry UA; Weber C; Hassan D; Gracely EJ; Kamareddine MH; Horn BI; Harper GR
Int J Cardiol Heart Vasc; 2022 Dec; 43():101130. PubMed ID: 36246771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
